Diacylglycerol acyltransferase 2 inhibitors
Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
1. A method for treating non-alcoholic steatohepatitis (NASH) in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof.
2. A method for treating non-alcoholic steatohepatitis (NASH) in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound comprising 3-((2-(3-(2-ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxamido)methyl)benzoic acid or (R)-3-((2-(3-(2-ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxamido)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 wherein said compound or pharmaceutically acceptable salt thereof is in admixture with at least one pharmaceutically acceptable excipient.
4. The method according to claim 2 wherein said compound or pharmaceutically acceptable salt thereof is in admixture with at least one pharmaceutically acceptable excipient.